Marcos José Pereira Renni¹*, André Nunes de Carvalho² and Wolney de Andrade Martins³

¹Doctor in Medicine by UFRJ, Scholarship Holder Researcher in the Clinical Research Division of the INCA, Brazil

*Corresponding Author: Marcos José Pereira Renni, Doctor in Medicine by UFRJ, Scholarship Holder Researcher in the Clinical Research Division of the INCA, Brazil.

Received: July 25,2022; Published: September 29, 2022

Abstract

Antineoplastic therapies can often lead to cardiovascular sequelae. Some patients present symptoms during cancer treatment, requiring immediate intervention to complete their treatment adequately and effectively.

Discussion: According to Cardinale., et al. 2013, patients undergoing chemotherapy treatment present a new cardiovascular risk factor, and as such, should be monitored like other traditional cardiovascular risk factors. Diagnostic methods for heart failure due to cardiotoxicity such as two-dimensional echocardiography, strain, and biomarkers are being used for early detection of myocardial damage. Once cardiac dysfunction is detected, it is necessary to intervene with drugs that improve myocardial function and thus enable the patient to finish the cancer treatment. New drugs recommended for the treatment of HF, can be used in these patients in addition to standard therapy, allowing a significant improvement in LVEF.

Conclusion: Cardio-oncology has also advanced in the last decade seeking to meet the demands generated by cancer therapies and improve the clinical conditions of patients. We believe that it is important to remember that cancer survivors exposed to potentially cardiotoxic therapies should be periodically monitored in the long term, since HF can develop several years after cancer therapy.

Keywords: Heart Failure; Cancer Patients; Diagnosis; Treatment

References

1. Zamorano JL., et al. “The cancer patient and cardiology”. European Journal of Heart Failure 12 (2020): 2290-309.
2. Radek Pudil., et al. “Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology”. European Journal of Heart Failure 22.11 (2020): 1966-1983.
3. Daniela Cardinale., et al. “Strategies to Prevent and Treat Cardiovascular Risk in Cancer Patients”. Seminars in Oncology2 (2013): 186-198.
4. Vanesa Gregorietti., et al. “Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy”. Cardiooncology1 (2020): 24.
5. Jelena Čelutkienė, Radek Pudil., et al. “Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)”. European Journal of Heart Failure 9 (2020): 1504-1524.
6. Ananthan, Kajaluxy and Lyon Alexander R. “The Role of Biomarkers in CardioOncology. Journal of Cardiovascular Translational Research”. Journal of Cardiovascular Translational Research 3 (2020): 431-450.
7. Dominik Berliner., et al. “Echocardiography and biomarkers for the diagnosis of cardiotoxicity”. Herz7 (2020): 637-644.
8. Raymundo A Quintana., et al. “Speckle-Tracking Echocardiography in Cardio-Oncology and Beyond”. Texas Heart Institute Journal 2 (2020): 96-107.
9. Stokkel MP., et al. “I-123-MIBG myocardial imaging in trastuzumab-based cardiotoxicity: the first experience”. Nuclear Medicine Communications 34 (2013): 19-24.
10. Arrais TR., et al. “MIBG cardiac imaging compared to ejection fraction in evaluation of cardiotoxicity: a systematic review”. Journal of Nuclear Cardiology (2021).
11. McDonagh TA., et al. “ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure”. Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure 1 (2022): 4-131.
12. Christina E Sheppard and Maria Anwar. “The use of sacubitril/valsartan in anthracycline-induced cardiomyopathy:A mini case series”. Journal of Oncology Pharmacy Practice 5 (2019): 1231-1234.
13. Ana Martín-Garcia., et al. “Effectiveness of sacubitril-valsartan in cancer patients with heart failure”. ESC Heart Failure 2 (2020): 763-767.
14. Faiez Zannad., et al. “SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials”. Lancet 10254 (2020): 819-829.
15. Husam M Salah., et al. “Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis”. Cardiovascular Diabetology 21 (2020): 20.
16. Irina Balan., et al. “Overview of SodiumGlucose Co-transporter 2 (SGLT2) Inhibitors for the Treatment of Nondiabetic Heart Failure Patients”. Cureus8 (2021): e17118.

Citation

Citation: Marcos José Pereira Renni., et al. “Heart Failure in Cancer Patients, from Diagnosis to Treatment". Acta Scientific Cardiovascular System 1.5 (2022): 38-42.

Copyright

Copyright: © 2022 Marcos José Pereira Renni., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.